

ABL-012.1P Sequence Listing.txt  
 SEQUENCE LISTING

<110> Hart, Stephen Lewis  
 Writer, Michele

<120> PEPTIDE LIGANDS

<130> ABL-012.1P US

<140> (To Be Assigned)

<141> 2005-12-06

<150> PCT/EP2004/002421

<151> 2004-06-07

<150> GB 03 13132.3

<151> 2003-06-06

<160> 50

<170> PatentIn version 3.1

<210> 1

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC\_FEATURE

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = any amino acid residue, Xaa at position 4 = any amino acid residue

<400> 1

Pro Xaa Xaa Xaa Thr  
 1 5

<210> 2

<211> 4

ABL-012.1P Sequence listing.txt

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> Xaa at position 3 = any amino acid residue

<400> 2

Pro Ser Xaa Ser  
1

<210> 3

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC\_FEATURE

<222> (2)..(4)

<223> xaa at position 2 = any amino acid, xaa at position 3 = any amino acid having an amide side chain, xaa at position 4 = any amino acid

<400> 3

Gln Xaa Xaa Xaa Gln  
1 5

<210> 4

<211> 3

<212> PRT

<213> Artificial Sequence

ABL-012.1P Sequence listing.txt

<220>

<223> Peptide ligand

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue having an aliphatic side chain

<400> 4

Ser Xaa Ser  
1

<210> 5

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 = any amino acid residue

<400> 5

Pro Xaa Leu Xaa Thr  
1 5

<210> 6

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 6

Pro Ala Leu Lys Thr  
1 5

<210> 7

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 = any amino acid residue

<400> 7

Pro Xaa Asn Xaa Thr  
1 5

<210> 8

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

ABL-012.1P Sequence listing.txt

<400> 8

Pro Ser Asn Ser Thr  
1 5

<210> 9

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 9

Pro Pro Asn Thr Thr  
1 5

<210> 10

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC\_FEATURE

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = any amino acid residue, Xaa at position 4 = any amino acid residue

<220>

<221> MISC\_FEATURE

<222> (6)..(6)

<223> Xaa at position 6 = any amino acid residue

<400> 10

Pro Xaa Xaa Xaa Thr Xaa  
1 5

ABL-012.1P Sequence listing.txt

```

<210> 11
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide ligand
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa at position 2 = any amino acid residue

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa at position 4 = any amino acid residue

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa at position 6 = any amino acid residue

<400> 11
Pro Xaa Leu Xaa Thr Xaa
1          5

<210> 12
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide ligand
<220>

```

<221> MISC\_FEATURE  
 <222> (2)..(2)  
 <223> Xaa at position 2 = any amino acid residue

<220>  
 <221> MISC\_FEATURE  
 <222> (4)..(4)  
 <223> Xaa at position 4 = any amino acid residue

<220>  
 <221> MISC\_FEATURE  
 <222> (6)..(6)  
 <223> Xaa at position 6 = any amino acid residue

<400> 12  
 Pro Xaa Asn Xaa Thr Xaa  
 1 5

<210> 13  
 <211> 6  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Peptide ligand  
 <220>  
 <221> MISC\_FEATURE  
 <222> (1)..(1)  
 <223> Xaa at position 1 = any amino acid residue

<220>  
 <221> MISC\_FEATURE  
 <222> (3)..(5)  
 <223> Xaa at position 3 = any amino acid residue, Xaa at position 4 = any amino acid residue, Xaa at position 5 = any amino acid residue

ABL-012.1P Sequence listing.txt

<400> 13

Xaa Pro Xaa Xaa Xaa Thr  
1 5

<210> 14

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Xaa at position 1 = any amino acid residue

<220>

<221> MISC\_FEATURE

<222> (3)..(5)

<223> Xaa at position 3 = any amino acid residue, Xaa at position 4 = any amino acid residue, Xaa at position 5 = any amino acid residue

<220>

<221> MISC\_FEATURE

<222> (7)..(7)

<223> Xaa at position 7 = any amino acid residue

<400> 14

Xaa Pro Xaa Xaa Xaa Thr Xaa  
1 5

<210> 15

<211> 7

<212> PRT

<213> Artificial Sequence



ABL-012.1P Sequence listing.txt

<220>

<223> Peptide ligand

<400> 15

Ala Pro Ser Asn Ser Thr Ala  
1 5

<210> 16

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 16

Ser Pro Ala Leu Lys Thr Val  
1 5

<210> 17

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 17

Ser Thr Pro Pro Asn Thr Thr  
1 5

<210> 18

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 18

ABL-012.1P Sequence listing.txt

Pro Ser Asn Ser  
1

<210> 19

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 19

Pro Ser Leu Ser  
1

<210> 20

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Xaa at position 1 = Ala or Lys

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 = any amino acid residue

<400> 20

Xaa Pro Ser Xaa Ser  
1 5

<210> 21

ABL-012.1P Sequence listing.txt

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 21

Ala Pro Ser Asn Ser  
1 5

<210> 22

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 22

Leu Pro Ser Leu Ser  
1 5

<210> 23

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 23

Met Leu Pro Ser Leu Ser  
1 5

<210> 24

<211> 7

<212> PRT

<213> Artificial Sequence

ABL-012.1P Sequence listing.txt

<220>

<223> Peptide ligand

<400> 24

Pro Met Leu Pro Ser Leu Ser  
1 5

<210> 25

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 25

Ser Gln Lys Asn Pro Gln Met  
1 5

<210> 26

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 26

Phe Gln Ser Gln Tyr Gln Lys  
1 5

<210> 27

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 27

Met Ala Ser Ile Ser Met Lys  
1 5

<210> 28

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 28

Asp Trp Trp His Thr Ser Ala  
1 5

<210> 29

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 29

Ser His Val Lys Leu Asn Ser  
1 5

<210> 30

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 30

Gln Leu Leu Thr Gly Ala Ser  
1 5

<210> 31

<211> 7

ABL-012.1P Sequence listing.txt

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 31

Thr Ala Arg Asp Tyr Arg Leu  
1 5

<210> 32

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 32

Phe Pro Arg Ala Pro His His  
1 5

<210> 33

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 33

Ser Glu Trp Leu Ser Ala Leu  
1 5

<210> 34

<211> 7

<212> PRT

<213> Artificial Sequence

ABL-012.1P Sequence listing.txt

<220>

<223> Peptide ligand

<400> 34

Ile Gly Gly Ile Arg Arg His  
1 5

<210> 35

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 35

Tyr Thr Met Glu Phe Asn Arg  
1 5

<210> 36

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 36

Pro Ala Ala Tyr Lys Ala His  
1 5

<210> 37

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC\_FEATURE

ABL-012.1P Sequence listing.txt

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = any amino acid residue, Xaa at position 4 = any amino acid residue

<220>

<221> MISC\_FEATURE

<222> (6)..(6)

<223> Xaa at position 6 = Ala or Val

<400> 37

Pro Xaa Xaa Xaa Thr Xaa  
1 5

<210> 38

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue,

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 = any amino acid residue,

<400> 38

Pro Xaa Asn Xaa Thr  
1 5

<210> 39

<211> 5



ABL-012.1P Sequence listing.txt

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC\_FEATURE

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = A  
sn or Leu, Xaa at position 4 = any amino acid residue

<400> 39

Pro Xaa Xaa Xaa Thr  
1 5

<210> 40

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> Xaa at position = Thr or Ser

<400> 40

Pro Xaa Asn Xaa Thr  
1 5

ABL-012.1P Sequence listing.txt

<210> 41  
 <211> 5  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Peptide ligand  
 <220>  
 <221> MISC\_FEATURE  
 <222> (1)..(1)  
 <223> Xaa at position 1 = Ala or Leu

<220>  
 <221> MISC\_FEATURE  
 <222> (4)..(4)  
 <223> Xaa at position 4 = any amino acid residue

<400> 41  
 Xaa Pro Ser Xaa Ser  
 1 5

<210> 42  
 <211> 5  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Peptide ligand  
 <220>  
 <221> MISC\_FEATURE  
 <222> (2)..(4)  
 <223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = A  
 sn or Gln, Xaa at position 3 = any amino acid residue

<400> 42

ABL-012.1P Sequence listing.txt

Gln Xaa Xaa Xaa Gln  
1 5

<210> 43

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = Leu or Ile

<400> 43

Ser Xaa Ser  
1

<210> 44

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 44

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Gly Ala Cys Ser His Val Lys Leu Asn Ser Cys Gly  
20 25

<210> 45

<211> 28

<212> PRT

<213> Artificial Sequence

ABL-012.1P Sequence listing.txt

<220>

<223> Peptide ligand

<400> 45

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Gly Ala Cys Ala Pro Ser Asn Ser Thr Ala Cys Gly  
20 25

<210> 46

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 46

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Gly Ala Cys Met Ala Ser Ile Ser Met Lys Cys Gly  
20 25

<210> 47

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 47

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Gly Ala Cys Phe Pro Arg Ala Pro His His Cys Gly  
20 25

<210> 48

<211> 28

ABL-012.1P Sequence listing.txt

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 48

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Gly Ala Cys Asp Trp Trp His Thr Ser Ala Cys Gly  
20 25

<210> 49

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 49

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Gly Ala Cys Arg Arg Glu Thr Ala Trp Ala Cys Gly  
20 25

<210> 50

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 50

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Gly Ala Cys Ala Thr Arg Trp Ala Arg Glu Cys Gly  
20 25